Evidence map›Paper›PMID 29177890›Full record

ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2018

AREDS simplified severity scale as a predictive factor for response to aflibercept therapy for typical neovascular age-related macular degeneration.

Yoichi Sakurada, Wataru Kikushima, Atsushi Sugiyama, Seigo Yoneyama, Naohiko Tanabe, Mio Matsubara, Hiroyuki Iijima

Abstract read
PubMed Publisher
In one paragraph

Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yoichi SakuradaDepartment of Ophthalmology, Faculty of Medicine, University of Yamanashi, Yamanashi Prefecture, Japan. sakurada@yamanashi.ac.jp.
Wataru KikushimaDepartment of Ophthalmology, Faculty of Medicine, University of Yamanashi, Yamanashi Prefecture, Japan.
Atsushi SugiyamaDepartment of Ophthalmology, Faculty of Medicine, University of Yamanashi, Yamanashi Prefecture, Japan.
Seigo YoneyamaDepartment of Ophthalmology, Faculty of Medicine, University of Yamanashi, Yamanashi Prefecture, Japan.
Naohiko TanabeDepartment of Ophthalmology, Faculty of Medicine, University of Yamanashi, Yamanashi Prefecture, Japan.
Mio MatsubaraDepartment of Ophthalmology, Faculty of Medicine, University of Yamanashi, Yamanashi Prefecture, Japan.
Hiroyuki IijimaDepartment of Ophthalmology, Faculty of Medicine, University of Yamanashi, Yamanashi Prefecture, Japan.

Funding

Japan Society for the Promotion of Science 26861441
6 · The paper itself

Abstract

purposeTo investigate whether the severity of the condition in the untreated fellow eye is a predictive factor for the response to intravitreal aflibercept injection (IAI) for exudative age-related macular degeneration (AMD).

methodsA retrospective medical chart review was conducted for 88 patients with treatment-naïve neovascular AMD, who were initially treated with three monthly IAIs, followed by monthly monitoring and re-injection as needed for at least 12 months. Subjects were classified into three groups according to the severity of the condition in their untreated eye, based on the severity scale in the Age-Related Eye Disease Study (AREDS): group 0, AREDS severity level 1 (no drusen); group 1, AREDS severity level 2 or 3 (any drusen); group 2, AREDS severity level 4 (advanced AMD). Genotyping was performed in all cases for ARMS2 A69S and CFH I62V.

resultsFellow-eye severity was associated with age and the risk variant of ARMS2 A69S (P = 0.005 and 0.001, respectively). Although best-corrected visual acuity (BCVA) had improved significantly after 12 months in all groups, this improvement was significantly greater in group 0 than in the other groups (P = 0.008). The retreatment-free period was also significantly longer for group 0 than for the other groups (P = 0.016), and the number of additional injections was significantly associated with fellow-eye severity (P = 0.007).

conclusionsFellow-eye severity was associated with treatment response in terms of visual improvement and retreatment and may be a predictive factor for response to IAI for neovascular AMD.

Indexed as

Visual AcuityAgedAged, 80 and overFemaleFollow-Up StudiesHumansIntravitreal InjectionsMacula LuteaMalePrognosisReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetreatmentRetrospective StudiesSeverity of Illness IndexTime FactorsafliberceptReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsAfliberceptAge-related macular degenerationARMS2 A69SFellow-eye severityRetreatment-free periodVisual improvement

Identifiers

PMID29177890

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.